JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v8i5.7336ArticleClinical Exploration of Immunosuppressants Combined with Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancerhttps://artdesignp.com/journal/JCNR/8/5/10.26689/jcnr.v8i5.7336MaLin2024852024-06-24Prostate cancer is a malignant tumor with a high incidence in elderly men. In recent years, with the improvement of people’s living standards and the advancement of detection technology, the incidence of prostate cancer has been increasing year by year. Castration-resistant prostate cancer (CRPC) is a highly challenging type of advanced prostate cancer treatment, which clinically shows resistance to hormonal deprivation therapy. The overall treatment efficacy of CRPC is currently poor and further relevant therapeutic studies are needed to improve patient survival and quality of life. Immunosuppressants can play a role in combating the immune system of tumors, and abiraterone has also achieved remarkable results in prostate cancer treatment. This study will investigate the possible clinical effects and safety of immunosuppressants combined with abiraterone in the treatment of metastatic CRPC. The population-based study will provide clinicians with more effective treatment options, as well as enhance the understanding of novel combination therapy strategies to be implemented in the future for such patients.

Zhang Y, Zhang J, Liao X, 2016, Comparison of Laparoscopic Rectal Transanal Drag-Out Surgery and Anterior Rectal Resection for Low Rectal Cancer. Chinese Journal of Minimally Invasive Surgery, 16(8): 736–739.

Feng P, Yang J, Tang M, et al., 2015, Impact of Tumor Site and Surgical Approach on Patients’ Prognosis After Neoadjuvant Radiotherapy for Progressive Low and Intermediate Rectal Cancer. Chinese Journal of General Surgery, 24(6): 895–898.

Pu Y, Qiu Y, Li X, et al., 2017, Retrospective Analysis of the Incidence, Recovery and Influencing Factors of Low Anterior Resection Syndrome After Anal Preservation Surgery for Rectal Cancer. Journal of the Third Military Medical University, 39(10): 1025–1030.

Zhang Z, Tian M, Yuan C, et al., 2016, Transabdominal Transanal Total Rectal Mesentery Resection Combined with Hepatic Metastasectomy for Simultaneous Low Rectal Cancer Liver Metastases. Chinese Journal of Digestive Surgery, 15(2): 123–127.

Han J, Wang Z, Gao Z, et al., 2016, Transabdominal and Perineal Double Laparoscopic Extra-Anal Rachii Muscle Abdominoperineal Combined Resection in Low Rectal Cancer. Chinese Journal of Gastrointestinal Surgery, 19(6): 654–658.

Cui W, Shi H, Zhang M, et al., 2022, Research Progress on the Role of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Chinese Medicine, 17(10): 1592–1596.

Hu X, 2022, Study on the Role of Tumor-Associated Macrophages in Tumors and Therapeutic Strategies. Medical Information, 35(20): 166–169.

Yang XL, Xue H, Yu Y, et al., 2022, Progress in the Study of Tumor-Associated Fibroblasts’ Cancer-Promoting Effects. International Journal of Laboratory Medicine, 43(18): 2292–2297.

Li H, Zhang M, Wang X, et al., 2022, Recent Advances in Therapeutic Agents for Metastatic Prostate Cancer. Chinese Journal of Male Science, 36(04): 101–107.

He H, Li C, 2021, Progress of Immune Checkpoint Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Zhejiang Med, 43(24): 2613–2618.